Sepsis is a life-threatening clinical syndrome and one of the most expensive conditions treated in hospitals. It is challenging to detect due to the nonspecific clinical signs and the absence of gold standard diagnostics. However, early recognition of sepsis and optimal treatments for sepsis are of paramount importance to improve the condition's management and patient outcomes. This paper aims to delineate key aspects of current sepsis detection systems, including their dependency on clinical expert and laboratory biometric features requiring ongoing critical care intervention, the efficacy of vital sign measures, and the effect of the study population with respect to the precision of sepsis prediction. The AUROC performances of XGBoost models trained on a heterogenous ICU patient group (n=3932) showed significant degradations (p<0.05) as the expert and laboratory biomarker features are removed systematically and vital sign features taken in ICU settings are left. The performance of XGBoost models trained only with vital sign features on a more homogeneous group of ICU patients (n=1927) had a significantly (P<0.05) improved AUPRC to moderate level. The presented results highlight the importance of making a practical machine learning system for sepsis prediction by considering the availability of dominant features as well as personalizing sepsis prediction by configuring it to the specific demographics of a targeted population.

Introduction There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiveness. Advances in biosensor technologies made it possible to continuously monitor physiological parameters using wearable biosensors with a variety of form factors.Objective To explore the potential of using wearable biosensors to continuously monitor multidimensional physiological parameters for early detection of COVID-19 clinical progression.Method This randomised controlled open-labelled trial will involve 200–1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong. Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period. In addition to fever and symptom surveillance in the control group, subjects in the intervention group will wear wearable biosensors on their arms to continuously monitor skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities. These physiological parameters will be transferred in real time to a smartphone application called Biovitals Sentinel. These data will then be processed using a cloud-based multivariate physiology analytics engine called Biovitals to detect subtle physiological changes. The results will be displayed on a web-based dashboard for clinicians’ review. The primary outcome is the time to diagnosis of COVID-19.Ethics and dissemination Ethical approval has been obtained from institutional review boards at the study sites. Results will be published in peer-reviewed journals.

More than 50% of the whole world lives with chronic diseases leading to a global economic burden of 47 trillion dollars. Healthcare organizations are moving towards managing patients outside hospital, thereby improving patient safety and quality of life. Current at-home ambulatory remote monitoring analytics based on population level thresholds of individuals physiology have shown poor outcomes and high degree of false alarm burden. The personalized multivariate physiology analytics leverages readily-available low-cost wearable biosensors to detect subtle physiology changes precursor of patient's health deterioration. In this paper we present a novel personalized multivariate physiology analytics for remote patient monitoring in an ambulatory setting. We also present our verification and validation results using perturbation testing along with clinical trial results.